Tissue | Expression Dynamics | Abbreviation |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00605417 | Esophagus | ESCC | respiratory system development | 123/8552 | 203/18723 | 1.26e-05 | 1.15e-04 | 123 |
GO:00303249 | Esophagus | ESCC | lung development | 109/8552 | 177/18723 | 1.40e-05 | 1.27e-04 | 109 |
GO:004671827 | Esophagus | ESCC | viral entry into host cell | 89/8552 | 144/18723 | 6.84e-05 | 5.18e-04 | 89 |
GO:000717810 | Esophagus | ESCC | transmembrane receptor protein serine/threonine kinase signaling pathway | 195/8552 | 355/18723 | 2.58e-04 | 1.58e-03 | 195 |
GO:00072299 | Esophagus | ESCC | integrin-mediated signaling pathway | 67/8552 | 107/18723 | 3.03e-04 | 1.81e-03 | 67 |
GO:19031317 | Esophagus | ESCC | mononuclear cell differentiation | 226/8552 | 426/18723 | 1.20e-03 | 5.88e-03 | 226 |
GO:00603485 | Esophagus | ESCC | bone development | 115/8552 | 205/18723 | 1.67e-03 | 7.72e-03 | 115 |
GO:00716347 | Esophagus | ESCC | regulation of transforming growth factor beta production | 28/8552 | 41/18723 | 2.88e-03 | 1.21e-02 | 28 |
GO:00336275 | Esophagus | ESCC | cell adhesion mediated by integrin | 45/8552 | 72/18723 | 2.97e-03 | 1.24e-02 | 45 |
GO:00716046 | Esophagus | ESCC | transforming growth factor beta production | 29/8552 | 43/18723 | 3.25e-03 | 1.35e-02 | 29 |
GO:0060021 | Esophagus | ESCC | roof of mouth development | 50/8552 | 85/18723 | 1.00e-02 | 3.42e-02 | 50 |
GO:00160328 | Lung | IAC | viral process | 94/2061 | 415/18723 | 5.11e-12 | 4.27e-09 | 94 |
GO:00071607 | Lung | IAC | cell-matrix adhesion | 63/2061 | 233/18723 | 7.08e-12 | 4.27e-09 | 63 |
GO:00315897 | Lung | IAC | cell-substrate adhesion | 85/2061 | 363/18723 | 8.57e-12 | 4.27e-09 | 85 |
GO:00190588 | Lung | IAC | viral life cycle | 77/2061 | 317/18723 | 1.23e-11 | 4.83e-09 | 77 |
GO:00521268 | Lung | IAC | movement in host environment | 48/2061 | 175/18723 | 1.30e-09 | 2.21e-07 | 48 |
GO:00517018 | Lung | IAC | biological process involved in interaction with host | 52/2061 | 203/18723 | 3.74e-09 | 5.84e-07 | 52 |
GO:00467188 | Lung | IAC | viral entry into host cell | 41/2061 | 144/18723 | 6.27e-09 | 9.08e-07 | 41 |
GO:0048875 | Lung | IAC | chemical homeostasis within a tissue | 11/2061 | 14/18723 | 7.44e-09 | 1.05e-06 | 11 |
GO:00444098 | Lung | IAC | entry into host | 42/2061 | 151/18723 | 8.80e-09 | 1.19e-06 | 42 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0451010 | Cervix | CC | Focal adhesion | 59/1267 | 203/8465 | 1.53e-07 | 1.84e-06 | 1.09e-06 | 59 |
hsa0481016 | Cervix | CC | Regulation of actin cytoskeleton | 64/1267 | 229/8465 | 2.24e-07 | 2.59e-06 | 1.53e-06 | 64 |
hsa051657 | Cervix | CC | Human papillomavirus infection | 74/1267 | 331/8465 | 1.70e-04 | 1.02e-03 | 6.03e-04 | 74 |
hsa0451014 | Cervix | CC | Focal adhesion | 59/1267 | 203/8465 | 1.53e-07 | 1.84e-06 | 1.09e-06 | 59 |
hsa0481017 | Cervix | CC | Regulation of actin cytoskeleton | 64/1267 | 229/8465 | 2.24e-07 | 2.59e-06 | 1.53e-06 | 64 |
hsa0516512 | Cervix | CC | Human papillomavirus infection | 74/1267 | 331/8465 | 1.70e-04 | 1.02e-03 | 6.03e-04 | 74 |
hsa0516510 | Esophagus | ESCC | Human papillomavirus infection | 215/4205 | 331/8465 | 7.86e-09 | 7.12e-08 | 3.65e-08 | 215 |
hsa0451020 | Esophagus | ESCC | Focal adhesion | 127/4205 | 203/8465 | 1.25e-04 | 4.99e-04 | 2.56e-04 | 127 |
hsa0481028 | Esophagus | ESCC | Regulation of actin cytoskeleton | 133/4205 | 229/8465 | 5.94e-03 | 1.48e-02 | 7.56e-03 | 133 |
hsa041517 | Esophagus | ESCC | PI3K-Akt signaling pathway | 197/4205 | 354/8465 | 1.24e-02 | 2.83e-02 | 1.45e-02 | 197 |
hsa0516515 | Esophagus | ESCC | Human papillomavirus infection | 215/4205 | 331/8465 | 7.86e-09 | 7.12e-08 | 3.65e-08 | 215 |
hsa04510111 | Esophagus | ESCC | Focal adhesion | 127/4205 | 203/8465 | 1.25e-04 | 4.99e-04 | 2.56e-04 | 127 |
hsa04810112 | Esophagus | ESCC | Regulation of actin cytoskeleton | 133/4205 | 229/8465 | 5.94e-03 | 1.48e-02 | 7.56e-03 | 133 |
hsa0415114 | Esophagus | ESCC | PI3K-Akt signaling pathway | 197/4205 | 354/8465 | 1.24e-02 | 2.83e-02 | 1.45e-02 | 197 |
hsa045108 | Lung | IAC | Focal adhesion | 59/1053 | 203/8465 | 1.31e-10 | 1.06e-08 | 7.06e-09 | 59 |
hsa051656 | Lung | IAC | Human papillomavirus infection | 71/1053 | 331/8465 | 1.88e-06 | 7.63e-05 | 5.06e-05 | 71 |
hsa0481012 | Lung | IAC | Regulation of actin cytoskeleton | 49/1053 | 229/8465 | 7.94e-05 | 1.17e-03 | 7.79e-04 | 49 |
hsa054126 | Lung | IAC | Arrhythmogenic right ventricular cardiomyopathy | 22/1053 | 77/8465 | 1.15e-04 | 1.49e-03 | 9.88e-04 | 22 |
hsa04512 | Lung | IAC | ECM-receptor interaction | 20/1053 | 89/8465 | 5.65e-03 | 2.45e-02 | 1.63e-02 | 20 |
hsa05410 | Lung | IAC | Hypertrophic cardiomyopathy | 20/1053 | 90/8465 | 6.44e-03 | 2.68e-02 | 1.78e-02 | 20 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ITGB6 | SNV | Missense_Mutation | novel | c.1727N>T | p.Cys576Phe | p.C576F | P18564 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A2-A4S1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ITGB6 | SNV | Missense_Mutation | rs756187131 | c.1754N>T | p.Ser585Phe | p.S585F | P18564 | protein_coding | deleterious(0) | probably_damaging(0.91) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
ITGB6 | SNV | Missense_Mutation | | c.1212N>C | p.Lys404Asn | p.K404N | P18564 | protein_coding | deleterious(0) | possibly_damaging(0.903) | TCGA-BH-A0DZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
ITGB6 | SNV | Missense_Mutation | rs552791527 | c.1916G>A | p.Gly639Asp | p.G639D | P18564 | protein_coding | tolerated(0.22) | benign(0.001) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ITGB6 | SNV | Missense_Mutation | rs760815776 | c.2344N>A | p.Val782Ile | p.V782I | P18564 | protein_coding | tolerated_low_confidence(0.44) | benign(0) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ITGB6 | SNV | Missense_Mutation | novel | c.716C>A | p.Pro239His | p.P239H | P18564 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-E2-A1LE-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | herceptin | PD |
ITGB6 | SNV | Missense_Mutation | rs376329044 | c.1910N>T | p.Ala637Val | p.A637V | P18564 | protein_coding | tolerated(0.22) | benign(0.174) | TCGA-E9-A1NG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | letrozole | SD |
ITGB6 | insertion | Nonsense_Mutation | novel | c.889_890insATATCAGTGAGGATAGCCGCATGTTGTCTTTTAGTCAGTGAGGG | p.Ser297AsnfsTer14 | p.S297Nfs*14 | P18564 | protein_coding | | | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD |
ITGB6 | insertion | Nonsense_Mutation | novel | c.471_472insACACATTATGCAGGTGATGGTGGAGGACAGATTGCTTTGTGA | p.Ser157_Arg158insThrHisTyrAlaGlyAspGlyGlyGlyGlnIleAlaLeuTer | p.S157_R158insTHYAGDGGGQIAL* | P18564 | protein_coding | | | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ITGB6 | SNV | Missense_Mutation | rs751132914 | c.821N>G | p.Ser274Cys | p.S274C | P18564 | protein_coding | deleterious(0.04) | probably_damaging(0.999) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3694 | ITGB6 | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE | inhibitor | 385612210 | | |
3694 | ITGB6 | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE | inhibitor | CHEMBL2109623 | STX-100 | |
3694 | ITGB6 | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE | antagonist | CHEMBL1743032 | INTETUMUMAB | |
3694 | ITGB6 | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE | | GLPG0187 | GLPG-0187 | |
3694 | ITGB6 | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE | inhibitor | CHEMBL2109621 | ABITUZUMAB | |